title: Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations.
abstract: Cerebrospinal fluid (CSF) carboxyterminally truncated amyloid-beta (Abeta) peptides, Abeta1-42 and tau protein were evaluated in 30 patients with frontotemporal lobe degenerations (FTLD), 30 Alzheimer's disease (AD) patients and 30 non-demented disease controls (NDC) by Abeta-SDS-PAGE/immunoblot as well as commercial ELISAs for Abeta1-42 and total tau. FTLD displayed a significant drop of Abeta1-37 (p = 2.7 x 10(-4)), Abeta1-38 (p = 4.2 x 10(-5)) and Abeta1-42 (p = 3.3 x 10(-4)). Abeta1-42 was selectively decreased in AD (p = 8.5 x 10(-10)). Decreased Abeta1-38 enabled contrasts of beyond 85% to distinguish FTLD from AD and NDC patients, alone or in combination. Accordingly, low CSF Abeta1-37 and Abeta1-38 represent a biomarker candidate for FTLD and may reflect disease-specific changes of APP metabolism. Further validation should be carried out on dementias other than AD, diagnostically relevant control groups without dementia and without any evident affection of the central nervous system and subgroups of FTLD. Moreover, independent methods of measurement should be applied to CSF Abeta1-38.
authors.affiliation: Department of Psychiatry, University of Goettingen, Goettingen, Germany. mbibl@gwdg.de
authors.forename: M
authors.initials: M
authors.lastname: Bibl
authors.forename: B
authors.initials: B
authors.lastname: Mollenhauer
authors.forename: S
authors.initials: S
authors.lastname: Wolf
authors.forename: H
authors.initials: H
authors.lastname: Esselmann
authors.forename: P
authors.initials: P
authors.lastname: Lewczuk
authors.forename: J
authors.initials: J
authors.lastname: Kornhuber
authors.forename: J
authors.initials: J
authors.lastname: Wiltfang
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid* / Q000737:chemistry; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002556:Cerebrospinal Fluid Proteins / Q000737:chemistry / Q000378:metabolism*; D003704:Dementia / Q000134:cerebrospinal fluid* / Q000175:diagnosis* / Q000503:physiopathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D015151:Immunoblotting; D008297:Male; D010446:Peptide Fragments / Q000134:cerebrospinal fluid; D010455:Peptides / Q000134:cerebrospinal fluid*; D011237:Predictive Value of Tests; D017434:Protein Structure, Tertiary; D016875:tau Proteins / Q000032:analysis / Q000134:cerebrospinal fluid
chemical_list: D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D015415:Biomarkers; D002556:Cerebrospinal Fluid Proteins; D010446:Peptide Fragments; D010455:Peptides; C078639:amyloid beta-protein (1-38); C075222:amyloid beta-protein (1-42); D016875:tau Proteins